We focus ondiscovering, developing and delivering drugs in therapeutic areas where we haveproven expertise and where we can have an impact. These areas include:

● GastrointestinalSystem

● CNS

● Otorhinolaryngology

And we are going toexpand our areas to:

● Oncology

● Endocrineand metabolism

● Immunology

● Cardiac-cerebralvascular disease

Pharscin Pharma places R&D and innovation higher on its agenda and has established a pharmaceutical research institute in ways that guarantee the successful implementation of research plans. Its R&D covers the research and development of TCM cultivation, extraction, classic prescription and preparations. In addition, it is also responsible for the research and development of chemical-drug  product lines of APIsand their preparations. These products cover therapeutic fields as varied as digestive system, neuropsychiatric system, ENT, Oncology, endocrine and metabolism regulation, cardiovascular and cerebrovascular systems. After years of operation, the company possesses strong technical industrialization transformation ability and is well capable of understanding Chinese laws and regulations on drug administrationand following theses regulations in everything it does. On top of that, the company has strong ability of drug registration and application that allows the company to quickly register domestic and foreign products. The company has built active partnerships with domestic and foreign companies in ways that jointly carry out research and development work in fields as varied as drug discovery and development, manufacturing process development, intelligent manufacturing, and drug clinical research. By doing so, the company is well-poised to embrace new opportunities and challenges brought about by the changes in the global pharmaceutical industry.

Pharscin Pharma Institute has research stationsfor academicians and post doctorates, with the coverage of 4,000 square metersand a total investment of nearly 100 million yuan.Ithas departments of TCM study, chemical APIs synthesis, finished pharmaceutical products,analytical quality, clinical study, information center and other departments.Each R&D professional platform has R&D labs and small and medium-scaletrial production workshops, realizing smooth transitionfrom new products andnew processes to industrialization.At the same time, Pharscin Pharma is equippedwith the Intellectual Property Department, the Drug Regulatory AffairsDepartment,and R&D Quality Management Department.Theinstitute now has nearly 100 researchers, including 5 Doctors and more than 20senior technical professionals.

The Pharmaceutical Research Institute has modernand advanced research and development facilities, including process researchequipment like CO2 supercritical extraction, fluidized bed coatingequipment for pellets, dry/wet high efficiency granulator, spray dryer, jetmill, capsule filling machine, rotary tabletingmachine, freeze dryer. In addition, it also hasanalytical testing equipment as varied as ultra high performance liquidchromatography, gas chromatography, GC-MS, atomic absorption spectrometer,laser particle size analyzer, moisture adsorption analyzer and thin layerscanner.Since its establishment,the company has successfully completed the industrialization research of aseries of new drugs. It is the "National Modern Engineering TechnologyPlatform for Chinese Medicine" and "Chongqing Municipal ModernEngineering and Research Center for Traditional Chinese Medicine" and"Chongqing Engineering Research Center for Traditional Chinese MedicineExtraction and Separation Technology"

The company has yield notable achievements inR&D.For more than a decade, the company has remainedcommitted to the combination of Chinese and Western technologies, and has paidcloser attention to the fields of digestive system, the neuropsychiatric systemand theotolaryngology. The company is now expanding its pipeline into fields as variedas cardio-cerebralvascular diseases, metabolic chronic diseases and oncology.Sinceits establishment, the company which startedwith one health care product approval has gradually obtained the first generic drug approvals  such as Weidimei ( HydrotalciteTablets /Chewable tablets), Changsong (Macrogol 4000Powder),Gabexate Mesylate for Injection and unique Chinese patent medicines likeDuliang Soft Capsules, Tongxiening Granules, Ganjuebingmei Tablets, Liuweianshen Capsules, and BaweiqilongGranules.Currently, it has 68 drugapprovals, including 49 drugs in the national "medical insurance"catalog, 46 drugs with domestic patents and one with the international patent.The R&D and project application team of thecompany has successively undertaken the high-tech industrialization project ofthe national development and reform commission, the "Twelfth Five-YearPlan" major new drug innovation projects of the Ministry of Science andTechnology, and research projects of the State Administration of TCM of the TCMindustry andnearly 100 scientific research projects ofChongqing Municipality.The company obtained two" National Patent Award" and one"Third Prize ofNational Prize for Progress in Science and Technology".

Enterprise Honor

Honors for Products